Your browser doesn't support javascript.
loading
Outcomes of adjuvant radiotherapy and lymph node resection in elderly patients with pancreatic cancer treated with surgery and chemotherapy.
Frakes, Jessica; Mellon, Eric A; Springett, Gregory M; Hodul, Pamela; Malafa, Mokenge P; Fulp, William J; Zhao, Xiuhua; Hoffe, Sarah E; Shridhar, Ravi; Meredith, Kenneth L.
Afiliação
  • Frakes J; Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL, USA.
  • Mellon EA; Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL, USA.
  • Springett GM; Gastrointestinal Tumor Program, Moffitt Cancer Center, Tampa, FL, USA.
  • Hodul P; Gastrointestinal Tumor Program, Moffitt Cancer Center, Tampa, FL, USA.
  • Malafa MP; Gastrointestinal Tumor Program, Moffitt Cancer Center, Tampa, FL, USA.
  • Fulp WJ; Biostatistics Core, Moffitt Cancer Center, Tampa, FL, USA.
  • Zhao X; Biostatistics Core, Moffitt Cancer Center, Tampa, FL, USA.
  • Hoffe SE; Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL, USA.
  • Shridhar R; University of Central Florida, Orlando, FL, USA.
  • Meredith KL; Surgical Oncology, Sarasota Memorial Health Care System, Florida State University College of Medicine, Sarasota, FL, USA.
J Gastrointest Oncol ; 8(5): 758-765, 2017 Oct.
Article em En | MEDLINE | ID: mdl-29184679
BACKGROUND: We sought to determine the effects of post-operative radiation therapy (PORT) and lymph node resection (LNR) on survival in patients ≥70 years with pancreatic cancer treated with surgery and chemotherapy. METHODS: An analysis of patients ≥70 years with surgically resected pancreatic cancer who received chemotherapy from the SEER database between 2004-2008 was performed to determine association of PORT and LNR on survival. RESULTS: We identified 961 patients who met inclusion criteria. There was a trend towards increased survival associated with PORT in all patients (P=0.052) and N1 patients (P=0.060) but no benefit in N0 patients (P=0.161). There was no difference in OS based on number of lymph nodes removed in all (P=0.741), N0 (P=0.588), and N1 (P=0.070) patients. MVA for all patients revealed that higher T stage, N1, and high grade tumors were prognostic for increased mortality, while there was decreased mortality with PORT and mild benefit with increased lymph nodes resected (P=0.084). CONCLUSIONS: PORT demonstrated no benefit in survival of pancreatic cancer patients ≥70 who are resected and treated with adjuvant chemotherapy. Future investigation will need to address age as a stratification factor for pancreatic cancer in the adjuvant setting.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article